AZD4956

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Solid TumorsSolid Tumours

Phase 1

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

RecruitingNCT07446855

AstraZenecaSolid Tumours

Start: 2026-03-17End: 2030-03-29Target: 180Updated: 2026-09-08

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)

Not yet recruitingCTIS2025-524171-22-00

AstraZeneca ABSolid Tumors

Target: 10Updated: 2026-08-20